Now showing items 1-2 of 2

    • A dose ranging trial to optimize the dose of Rifampin in the treatment of tuberculosis 

      Boeree, Martin J; Diacon, Andreas H; Dawson, Rodney; Narunsky, Kim; du Bois, Jeannine; Venter, Amour; Phillips, Patrick P J; Gillespie, Stephen H; Mc Hugh, Timothy D; Hoelscher, Michael; Heinrich, Norbert; Rehal, Sunita; van Soolingen, Dick; van Ingen, Jakko; Magis-Escurra, Cecile; Burger, David; Plemper van Balen, Georgette; Aarnoutse, Rob E (2015-05-01) - Journal article
      Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on pharmacokinetic, toxicity and cost considerations. Available data in mice and humans showed that an increase in dose may shorten the duration of ...
    • Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations 

      Svensson, Robin J; Svensson, Elin M; Aarnoutse, Rob E; Diacon, Andreas H; Dawson, Rodney; Gillespie, Stephen H; Moodley, Mischka; Boeree, Martin J; Simonsson, Ulrika S H (2018-04-28) - Journal article
      Background The currently recommended rifampicin dose (10 mg/kg) for treating tuberculosis is suboptimal. The PanACEA HIGHRIF1 trial evaluated the pharmacokinetics and early bactericidal activity of rifampicin doses of up ...